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IMPACT EVALUATION OF INTERNATIONAL MULTIDISCIPLINARY 
TUMOR BOARDS 
JASON A. SREEDHAR 
ABSTRACT 
 
 Over the last 20 years, cancer clinicians have begun to improve the efficacy of 
cancer care through tumor boards, meetings of multidisciplinary patient care teams used 
to educate attendees and align treatment plans.  In addition to the potential for 
collaboration between different disciplines, these meetings allow for the incorporation of 
information from peer-reviewed literature.  Despite their use, very little research has been 
done on the effect of tumor boards on treatment efficacy.  Within this small body of 
work, the indicators used are often inherently biased, and little concern is given to their 
confounding effects.  This document will discuss alternative metrics that provide a less 
biased estimate of the impact of tumor boards. 
 Given their educational aspects, tumor boards are beginning to be used in an 
international context to support clinicians in developing nations.  Despite the relative lack 
of evidence supporting use of tumor boards, they provide a low-cost method for 
improving clinician education in a setting where treatment protocols vary greatly.  
Moreover, international tumor boards provide a way for low-resource hospitals to tap into 
facilities of high-resource hospitals, receive resource-sensitive guidelines for future 
practice, and collaborate with clinicians from other hospitals.  However, there are serious 
barriers to implementing international tumor boards, including technological, logistical, 
linguistic, and oversight issues.  This document outlines potential issues and methods to 
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circumvent them, as well as benefits of international tumor boards (including future 
collaboration). 
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INTRODUCTION 
 In the development of better care of cancer patients, the involvement of 
multidisciplinary cancer conferences (MCCs), otherwise known as “tumor boards” 
(TBs), has become commonplace in may parts of the world.1, 50  These conferences, 
which aim to improve patient care by enhancing clinician education and 
collaboration, bring clinicians of many specialties (radiology, pathology, radiation 
oncology, medical oncology, surgery) together for discussion of patient cases.36  
These meetings enable collaboration of practitioners, culminating in their provision of 
a multimodal consensus treatment supported by peer-reviewed literature.30  The main 
objectives of these meetings are to improve patient care, further educate trainees and 
faculty, and standardize treatments of a given disease.12  Moreover, TBs allow for 
multidisciplinary collaboration in order to improve integration of multiple 
components patient care (nursing, psychosocial care, social work, etc). 
 Tumor boards are generally structured to involve both case-based discussion 
of diagnoses and treatments (both prospective and retrospective cases) and evidence-
based teaching sessions to familiarize attendees with the literature surrounding a 
given topic.35  Through the use of both didactic teaching and interactive case 
discussions, the information shared during the tumor board regarding a specific 
cancer type is reinforced multiple times.  Attendees of TBs should come from 
multiple different oncology-related specialties, thus allowing improved education and 
integration across all aspects of cancer care. This list can include physicians in 
radiation oncology, surgical oncology, medical oncology, internal medicine or 
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pediatrics (with subspecialization in the neoplastic organ being discussed), pathology, 
and radiology. This group of physicians should be supplemented by specialist nurses, 
social workers, medical trainees, psychologists, and other members of the care team 
as needed.  Having multiple specialties and training levels present at a TB allows for 
a more holistic discussion of how to proceed with the patient’s care, as well as 
continuation of this collaborative methodology through incorporation of trainees.28  
 At present, there is only a small amount of published literature regarding 
tumor boards.30  Despite the Calman-Hine ruling of 1995, which mandated the use of 
TBs across the United Kingdom, very few studies on the effectiveness of TBs have 
been conducted since this ruling.45  Most of the existing literature use “before and 
after” metrics, which measure what effect the TB had on the proposed diagnosis and 
treatment, rather than patient outcomes.11 While valuable, this metric is not a stand-
alone metric given the countless biases that are inherent within its measurement and 
analysis, and therefore should be used only in conjunction with other measures. Thus, 
use of an indicator containing such biases leads to the inherent limitation in scope of 
current TB effectiveness literature.  Despite the push for increased use of TBs to 
coordinate care, evaluation of TBs has not been carried out in a scientifically rigorous 
manner. 
Another threat to the validity of TB effectiveness literature is that a set 
structure or constitution for tumor boards does not exist, causing high levels of 
variation between different TBs.   Croke et al. make note of variations between TBs, 
such as available technological and therapeutic resources, and how this creates 
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variation in the projected impact of different TBs. 11  As a result, the existing data on 
TB effectiveness remains both small in size as well as highly variable. 
 As low- and middle-income countries look for ways to improve their quality 
of care, tumor boards present a method for advancement through coordination of care 
and generation of resource-sensitive care models.  Despite the lack of valid 
effectiveness research on TBs, these conferences provide a method for collaborating 
with clinicians from the developed world in order to improve training and education 
levels within their own staff.  Given that there are significantly fewer physicians as 
well as training programs in the developing world, care-givers are often less sub-
specialized than their developed world counterparts, leading to frequent variation in 
treatment regimens between physicians.14 Additionally, as financial challenges may 
arise in purchasing frontline diagnostics and drugs, physicians in resource-limited 
settings are often faced with uncertainty when selecting alternative therapies, for 
which little data exist.52  Through collaborative international tumor boards, hospitals 
of undeveloped nations can pair with those of more developed nations in order to 
provide more post-graduate training, standardize care via resource-sensitive 
guidelines, and identify the most effective alternative therapies as outlined by peer-
reviewed literature.13  In this way, international tumor boards (ITBs) provide a 
collaborative platform for improving international cancer care. 
 TBs are projected to be highly effective in improving the quality of patient 
care, as shown by a number of previous studies.  According to Wright et al., these 
conferences are “integral to patient process and patient outcomes”, improving patient 
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outcomes, physician education, and patient satisfaction in addition to other 
indicators.51  While this does provide a great avenue for improving the quality of care, 
more rigorous quantitative analysis must be used to ensure that the expected progress 
is in fact being made.  As with any other intervention, data-driven statistical 
approaches and more quantitatively-focused outcome analysis are needed to prove 
that tumor boards are improving cancer care, both in regards to patient care and 
physician education.11  This thesis serves to discuss the methods whereby we may 
more appropriately measure the impact of tumor boards, as well as the 
implementation of tumor boards and effective impact evaluation in the resource-
limited context of low- and middle-income countries.  Specific attention will be given 
to the structure of TBs, the hypothetical attendees, the methodology for measuring the 
impact of TBs on patient care, and potential issues that would arise when 
implementing and evaluating TBs in the developing world.   
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Specific Aims and Objectives 
1. Outline how tumor boards work: structure, function, attendees 
 
2. Identify the metrics that are currently used in local tumor boards, including 
rationale and confounding variables 
 
3. Discuss how different tumor boards have performed on these scales 
 
4. Examine the potential benefits and drawbacks of applying tumor board construct 
on an international scale 
 
5. Identify the problems faced by low- and middle-income countries and how these 
problems could alter the aforementioned metrics 
 
6. Generate a new set of metrics that should be used for international TBs: define 
metrics, identify the underlying constructs being measured, examine possible 
confounding factors 
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OVERVIEW OF TUMOR BOARDS 
 As stated by De Guzman, the main objective of TBs is to utilize literature-
based discussions as well as patient cases in order to improve the quality of care.12  
This is done via the use of both retrospective and prospective case discussions as well 
as short teaching sessions outlining existing research, diagnostics, and therapeutics 
for a given cancer subtype.35  Through the discussion of appropriate diagnostic 
methodology and therapeutic approaches in patient care, these conferences aim to 
improve the quality of care by improving clinician knowledge of appropriate clinical 
care protocols and algorithms for a given cancer or developing such guidelines.12   
Attendance and Structure 
 In his discussion of the attendees of a tumor board, Jazieh explains that the 
objective of having physicians of multiple disciplines and treatment modalities 
present is to improve the knowledge base present within the room; ideally, the 
multidisciplinary collaboration would allows the multiple aspects of cancer care to 
work together in a more cohesive manner, leading to better patient care.28  To this 
end, Jazieh suggests involving physicians from many different specialties, who 
should be joined by other clinical staff when appropriate.28  Participation from 
trainees and junior physicians should be particularly emphasized in view of the need 
for training.  Incorporating as many aspects of patient care as possible allows for 
greater cross-talk between care providers.  Furthermore, Jazieh suggests that multiple 
clinicians be present from each discipline, allowing for educational mini-discussions 
regarding a given field by multiple physicians trained in that field.28  Furthermore, 
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Jazieh suggests that multiple clinicians of each discipline be present.28  Having 
multiple clinicians from a given discipline allows for cross-talk between peers, 
enhancing the quality of the discussion by providing multiple perspectives regarding 
treatment protocols, patient management, etc.28 Lastly, in addition to the 
aforementioned attendees, an additional participant should serve as the tumor board 
leader, who facilitates discussion surrounding the cases and encourages participation 
from all parties.26, 28  Ideally, the physician caring for the patient would fill this role, 
but this does not have to be the case. 
 As previously mentioned, the main function of tumor boards is to discuss 
how/when to apply existing treatment protocols to cases, or to develop new protocols 
should they not exist for a certain case. Thus, TBs should be structured in such a way 
that facilitates this knowledge transfer.   The main components of tumor boards 
include introductions (when attendees do not know each other), didactic teaching 
sessions, discussion of the patient’s initial presentation, analysis of diagnostics 
(including pathology and radiology), review of the patients treatment regimens, and 
concluding remarks on the case.  Other components can be added, but these are the 
essential aspects of a TB. 
In order to prepare attendees for a TB, Halsted et al. mention the need for 10-
page written reports, including radiology and pathology images, to be disbursed one 
week before the date of the TB.  This policy allows all participants to have some 
previous knowledge of the case and better prepare for the TB, and results in better 
participation.24  The didactic teaching component of the TB should rely heavily on 
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published quantitative data (in addition to qualitative measures) in order to provide 
background for the cases being discussed.23  The ensuing case studies should then 
serve as a means to discuss the implementation of the didactic material.43   Case 
discussions should include an review of the initial presentation by the covering 
physician (including all tests and diagnostic procedures), a discussion by the 
radiologist and pathologist of all images and slides (including the criteria on which 
the diagnosis was made), and a discussion of what treatment options have been 
explored by the surgeon, radiation oncologist, and medical oncologist.28  The input of 
the pathologist and radiologist is crucial here, given their highly important role in 
establishing an accurate diagnosis.   
Given the teaching objective of TBs, participation from junior staff should be 
encouraged throughout the conference.  Trainees and junior physicians should be 
expected to present cases as well as head didactic sessions during the TBs.  Doing so 
provides residents and fellows with a sense of ownership and responsibility over the 
material presented while limiting the preparation time required of senior staff.23 
Objectives and Effectiveness 
 Despite a small body of research on TBs, a subset of literature utilizing 
before-and-after metrics for TBs has shown that TBs may improve patient 
management and quality of patient care (Table 1).  Newman et al.  reported that a 
breast cancer TB based out of the University of Michigan (N=149) resulted in 
changes in surgical management in 32% of patients, and chances in  pathological 
diagnosis in 29% of cases; these results imply an improved level of care due to the 
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literature survey and multidisciplinary case review.35  Many other studies have been 
employing the same “before-and-after” indicators, which identify the percentage 
change in diagnosis, staging, or treatment plan of cancers as a result of tumor boards.  
Most of these studies show that TBs change the management of a significant number 
of cases in one of these criteria, suggesting that these changes may allow for a higher 
level of care as a direct result of multidisciplinary collaboration. Van Hagen et al. 
mention an upper GI tumor board discussions causing treatment plan changes in 34% 
of cases (N=171), while Wheless et al. noted a head and neck TB (N=120) encourage 
care-givers to alter 25% of diagnosis/staging decisions and 18% of treatment  
plans.47, 49  Similarly, Chang et al. mention that in a breast tumor board held by the 
University of Pennsylvania, 43% of proposed therapeutic plans presented (N=77) 
were disputed between physicians.8 Similar results are echoed by countless other 
articles.  All of these studies show higher numbers of cases facing stricter scrutiny 
and analysis as a result of TBs, implying that enhanced discussion allows for better 
care.  Moreover, these studies point to variability in care between physicians and the 
need for standardization guided by literature, a service provided by TBs.   
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Table 1: Studies of TB Efficacy Utilizing “Before-and-After” Indicators 
Authors Type of Cancer Study Size Main Findings 
Newman et 
al. 
Breast 149 32% change in surgical mgmt. 
29% change in path. diagnosis 
Van Hagen 
et. al 
Upper GI 171 34% change in treatment plans 
Wheless et 
al. 
Head/Neck 120 25% change in 
diagnosis/staging 
18% change in treatment plans 
Chang et al. Breast 77 43% of therapy plans disputed 
Ganesan et 
al.  
Ovarian 108 37% change in path. grade of 
tumor 
52% change in diagnosis 
22% change in overall mgmt. 
Gatcliffe et 
al. 
Multiple types 153 18% change in diagnosis 
26% need further discussion 
Pawlik et al. Pancreatic 203 23% change in overall mgmt. 
25% change in treatment 
Wright et al.  Multiple types Unknown 7-43% change in overall mgmt. 
While most studies have utilized “before-and-after” indicators to measure the 
impact of tumor boards, few have used patient outcomes (the ultimate goal of TBs) to 
evaluate the efficacy of TBs (Table 2).  Stephens et al. reported that an esophageal 
TB (N=54) decreased operative mortality from 26% to 5.7% while increasing 5-year 
survival from 10% to 52%.43  In a study of non-small cell lung cancer, Forrest et al. 
showed that TBs (N=243) doubled patient life expectancy to from 3.2 months to 6.6 
months.19  Junor et al. reported that patients presented at a multidisciplinary TB 
(N=479) were more than twice as likely to get the appropriate treatment (platinum 
treatment) for their ovarian cancers.29  Outside of the field of oncology, Traynor et al. 
mention a multidisciplinary clinic for ALS patients (N=344) causing a 30% decrease 
in mortality and a 7.5-month increase in lifespan for patients.46  This body of work 
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shows that a multidisciplinary approach to disease, specifically to cancer, can extend 
the lives of patients. 
Table 2: Studies of Tumor Board Efficacy Utilizing Patient Outcome Indicators 
Authors Type of Cancer Study 
Size 
Main Findings 
Stephens et al. Esophageal 54 20.3% drop in operative mortality 
42% increase in 5-year survival 
Forrest et al. Lung (non-small 
cell) 
243 106% increase in life expectancy 
Junor et al. Ovarian 479 100% more likely to receive 
appropriate treatment 
Traynor et al. ALS (non-
cancerous) 
344 30% decrease in 1-year mortality 
 
Drawbacks 
 One of the major issues with existing tumor board literature is the variability 
between physicians, hospital systems, and tumor boards themselves.  Speaking on this 
subject, Croke address the relative weakness of existing data in saying, “available 
data are weakened by the heterogeneity and vagueness of the studies and their ill-
defined endpoints and large number of confounding variables…As a result, firm 
conclusions can not be drawn”.11  While many tumor boards do report positive 
outcomes as a result of their discussions, an equally large number report changes that 
are either statistically insignificant (despite being adequately powered) or all-together 
nonexistent.  Nguyen’s study of a TB from the University of Arizona discussing head 
and neck cancers showed an improvement in 3-year survival by only 8% for 
surgery/radiation combination therapy and 7% for chemotherapy, a finding shown to 
be statistically insignificant.36  A study by Birchall et al. of the South West Cancer 
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Intelligence Service Tumor Panel (UK) comparing a pre-Calman-Hine cohort in 1997 
(no TB) to a post-Calman-Hine cohort in 2000 (with TB) showed nearly identical 
survival rates; this finding indicates that the presence of TBs did not impact patient 
care.6  A study by Keating et al. of 138 US-based Veterans Affairs Hospitals also 
showed no significant impact of tumor boards via the use of 27 different 
performance-based metrics.30  The ambivalent data from these studies, in conjunction 
with other data showing a positive impact of tumor boards, portray the image of a 
highly variable field in which little is definitively known. 
 The reasons underlying this disparity and variability in data are not well 
understood.  Factors could include heterogeneity in disease stage upon initial patient 
presentation, resource availability, existing comorbidities, advances in therapies, 
profile of attendees, hospital-specific treatment protocols, etc.11  Thus, in order to 
generate a larger and more consistent body of data on the impact of TBs, better 
metrics need to be developed and applied appropriately.  While tumor boards are 
speculated to improve patient outcome, overall care protocol development, and 
physician education, results derived from data pertaining to these topics continues to 
be inconclusive.  These improved metrics will allow for greater external validity, 
providing a better picture of TB effectiveness. 
 In addition to the variations affecting the measurement of impact of TBs, there 
are other factors intrinsic to TBs that mitigate the effectiveness of the tumor boards 
themselves; studies of these factors have lead to conflicting reports on whether TBs 
are greaten or worsen the timeliness of cancer treatment.  Various studies have listed 
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concordance rates (percentage of TB-based consensus treatments that are actually 
carried out) between 85% and 98%.7, 9  Many of these discrepancies are due to 
unforeseen patient comorbidities.  Due to their deviation from the optimally effective 
consensus treatment, they will invariably affect the data derived fro tumor boards.  
Another major factor that may diminish the impact of tumor boards on patient 
outcomes is the wait time caused by increased imaging and pathological 
workup/review on each patient.6 Given that cases presented at TBs are generally more 
severe, this delay could be quite damaging.  According to van Hagen et al., the 
additional work-up required by TBs can cause a 20-day to 5-week delay in treating a 
patient.47  Despite these findings, Gabel et al. have reported a shortening in treatment-
start time (time from diagnosis to treatment initiation) from 42 days to 30 days, 
partially as a result of the increased physician assurance provided through tumor 
boards.20  Birchall et al. mention that while this is not likely to alter survival rates, it 
will have some effect on the morbidity and quality of life for the patient.6  Thus, 
current research is unclear on whether the need for more workup in TB cases 
positively or negatively affects the quality of care delivered. 
 All in all, these factors add to the variability of TB-based data in addition to 
obscuring the impact of the conferences.  While the root causes of these issues can 
not be eliminated, steps can be taken to reduce their influence as well as measure their 
effect via the use of better control groups.  This topic will be discussed later when 
outlining new metrics for tumor boards.  
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CRITERIA OF DOMESTIC TUMOR BOARDS 
 As mentioned above, the metrics used to evaluate the effectiveness of tumor 
boards are highly variable.  Moreover, some of these indicators are subject to bias, 
thereby limiting their validity.  The following section will serve as an overview of the 
criteria being used to analyze internal tumor boards in peer-reviewed literature, as 
well as to promote the use of new indicators. 
 Much of the existing literature on tumor boards uses a “before-and-after” 
model of evaluation, measuring the effect of the TB in changing either the diagnosis, 
staging, or treatment plan for a given cancer.  This is often (but not always) 
accompanied with some kind of rating scale to measure how drastic this change is.  In 
a survey of high-resource Arab hospitals, El Saghir et al. concluded that tumor boards 
evaluated through “before-and-after” indicators cause change in 
diagnosis/management or treatment in of 33-50% of cases; however, this seems to be 
much higher than the measurements of other studies based in the US.14 In the head 
and neck tumor board of University of North Carolina, studied by Wheless et al., 
resulted in a change rate of  25% (diagnosis) and 18% change in treatment plan.49  
Van Hagen’s study of an upper-GI tumor board revealed a 34% change in treatment 
plan, including a 35% change of modality only.47  Chang’s study of multidisciplinary 
breast cancer management at the University of Pennsylvania showed a 43% change in 
diagnosis and a 45% change in treatment.8  A similar study at the University of 
Michigan by Newman et al. showed a 29% change in pathological diagnosis and a 
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32% change in surgical management.35  Thus, as mentioned by Croke before, before-
and-after studies show highly heterogeneous results.11 
 In a study of multidisciplinary lung cancer management, Coory address this 
variability by saying: 
Before-and-after studies provided relative weak evidence of a causal 
association because of the potential for confounding. Specifically, multiple 
concurrent changes in cancer care over time, such as increased specialization, 
better treatments, or increased adherence to evidence-based guidelines, could 
be the reason for apparent improvement in survival, rather than the 
introduction of a MD team. Use of historical controls can introduce a bias 
known as the ‘Will Rogers phenomenon’, resulting from more accurate 
staging of more recent patients. This might account for the drift towards more 
advanced disease observed…10 
 
Abdulrahman Jr. et al. reinforces this idea, stating that “before-and-after designs… 
are considered as weak evidence for determining causal relationships because of 
multiple potential confounders.1 New designs should be looked into in future studies 
and there should be an adjustment for any confounder in case-control studies.”1  Both 
authors make note of the high prevalence of confounding variables that are 
unaccounted for, resulting in the aforementioned variation in before-and-after impact 
estimation.  As a result of this, newer and more accurate measures of tumor board 
impact need to be developed to replace the current before-and-after metric. 
 A review paper by Croke et al. further demonstrates the effect of confounding 
factors in before-and-after studies.11  In its discussion of many studies covering a 
broad range of cancer types, this paper mentions both a gynecological cancer paper 
by Gatcliff, showing case alterations in 35% of cases as a result of a TB, as well as a 
genitourinary cancer paper by Archer showing case alterations in less than 2% of 
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cases.6, 23  Comparison of two studies showing significantly different results within 
the same indicator further shows the variation between studies as well as the 
influence of confounding and unknown factors on impact evaluation or TBs. In 
addition to further demonstrating the aforementioned point, Croke et al. bring up 
another key flaw of the before-and-after metric by stating, “the authors [of a paper 
using before-and-after metrics] did not assess whether the changes in management 
affected patient care and survival”.11  Many studies employing “before-and-after” 
metrics do not include information about patient morbidity and mortality, 
demonstrating that these indicators are not targeting the constructs they should be 
evaluating.  This brings up the point that before-and-after studies are only relevant if 
and when it is shown that these changes create a higher quality of cancer care. 
 These “before-and-after” metrics, which are used in conjunction with 
measures of attendance at TBs, are currently being used in evaluation despite high 
levels of variation and confounding (Table 3).  As research on TBs continues, better 
indicators are needed to develop a realistic idea of the effect of TBs and their 
effectiveness in qualitatively enhancing cancer care.  
Table 3: Commonly Employed Indicators for Non-Collaborative Tumor 
Boards: 
1. “Before-and-after” change in treatment plan and management 
2. “Before-and-after” change in prognosis (as guided by pathology services) 
3. Attendance 
 17 
 
In regards to alternate metrics for tumor boards, a review by Croke et al. 
outlines a series of studies spanning many types of cancer that use metrics other than 
before-and-after measurements (Table 4).11 The authors also cover studies employing 
alternative and uncommon metrics, including physician concordance with TB 
consensus treatment suggestions, long-term survival rates (2, 3, and 5 years), 
operative mortality, and time from diagnosis to treatment initiation, with all of these 
studies comparing patients receiving TB recommendations to those who did not.11  
Moreover, Ribeiro and Ching-Hon’s discussion of twinning partnerships brings up 
tumor relapse rate and toxicity death rate as important metrics for evaluating cancer-
related interventions.39  Fader et al. also introduce the idea of looking at TB-
associated cases from a financial standpoint, mentioning both cost-benefit analysis as 
well as spending patterns.16 While economic analysis would beneficial on a policy-
making level, it is outside the scope of an individual physician’s work and is thus 
excluded here. Employment of the aforementioned alternative metrics (physician 
concordance, tumor relapse rate, toxicity-based death rate, operational mortality, 
long-term survival, diagnosis-treatment time) allows for expansion of knowledge 
surrounding TBs via the ability to better target at what levels they do or do not 
improve care.   
  Regarding case selection, many authors note that only the most severe cases 
should be presented in order to maximize time-efficiency.  Case selection criteria 
should only allow cases that are either highly complex in presentation, irregular in 
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presentation, or recurring.22, 33  Thus, less than 10% of the total case-load should be 
presented at a tumor board.31  Thus, as a result of the complexity and severity of cases 
presented at tumor boards, survival metrics are expected to be lower than that over 
the overall cancer patient population at a given care center.22 
 The remainder of this section will serve to individually outline each of these 
metrics, discussing their main analytic objective, current state, and potential 
confounding factors. 
 
 
 
 
Table 4: Proposed Alternative Metrics for Tumor Boards (Collaborative and 
Non-collaborative): 
1. “Physician concordance”-- concordance between the TB suggestions and 
the used treatment protocol 
2. 3-year tumor relapse rate 
3. Toxicity-based death rate/operative mortality 
4. Long-term survival 
5. Diagnosis-treatment time (time from diagnosis to treatment initiation) 
6. Before-and-after” change in diagnosis 
7. “Before-and-after” change in treatment and management plan 
8. Qualitative Indicators 
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Physician Concordance with TB Consensus Treatment 
 Through documentation of TB consensus and follow up on individual 
patients, concordance between the TB-based consensus and final treatment plans can 
be studied.  Analysis of concordance data allows for study of the effect of TB 
recommendations on physician decision-making; assuming that TBs always give 
literature-based suggestions that provide the highest quality of care, concordance 
percentages measure whether this high standard is carried through to the patient’s 
care in its entirety.   Studies of domestic tumor boards, almost entirely from high-
resource countries, show that concordance varies from 85% of 98% (Table 5).6, 7  As 
explained by Wood et al., the main confounders in physician concordance (causing 
deviation from TB consensus treatment plans) include comorbidities not mentioned at 
the TB, newly-discovered metastases,  and patient choice.50  As previously 
mentioned, cases presented at tumor boards should be the most complex cases seen, 
whether as a result of advanced stage, comorbidity, or other factors.  As a result, these 
cases often need the most work-up and monitoring of overall health.  Given that the 
most common cause of discord between consensus and final treatments are newly-
discovered metastases (an issue more prevalent in advanced-stage cancers) and 
decompensation due to comorbidities (more common in complex cases), in addition 
to the case selection process used to select only complex cases, tumor boards as a 
whole should expect to see lower concordance percentages due to the complexity of 
cases presented.50 
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 The physician concordance indicator, as mentioned by Croke et al., is 
beginning to gain credence, as it is being used increasingly to measure TB impact.11  
While this measure is inherently biased, its use in conjunction with other indicators 
gives a clearer picture of how the discussions of tumor boards relate to the quality of 
cancer care.  
Table 5: Studies of Tumor Board Efficacy Utilizing Physician Concordance 
Authors Type of 
Cancer 
Study 
Size 
Findings 
Blazeby et al. Upper GI 273 85% Concordance with consensus,  
patient choice and undiscovered 
comorbidity leading causes for 
discordance 
Strong et al. Upper GI 333 86% concordance with consensus, 
discordance usually due to 
decompensation 
Schroeder et 
al. 
Breast and 
Gynecological 
479 78% full concordance, 98% partial 
concordance, discordance most 
commonly due to patient 
deterioration 
Tumor relapse rate (3-year) 
 The utility of measuring the rate at which patients relapse from any given 
treatment is that is provides information on what treatments are useful for any given 
cancer type and stage.  This has additional implications for the developing world, 
which will be discussed later. Having this information allows the guidance of further 
tumor boards based on past evidence.  For example, if tumor board physicians note 
that a chemotherapy regimen has a high relapse rate, additional drugs or other 
treatment modalities could be added to lower the rate of relapse and improve long-
term health.  While this indicator has not been previously used in the evaluation of 
tumor board effectiveness, it has been mentioned as a method to measure efficacy in 
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inter-hospital twinning partnerships, and showed positive outcomes in a partnership 
between Saint Jude Children’s Research Hospital and Recife Hospital in Brazil.39  
These twinning partnerships will be further explored later. 
Toxicity-based Death Rate and Operative Mortality (3-year) 
 Given that chemotherapy and radiation therapy can be highly destructive to 
the body of the patient, an indicator to measure the toxicity of these treatments should 
be employed in a tumor board.  Similar to the tumor relapse rate, collecting and 
documenting the toxic effects of a given treatment/management regimen can help 
guide recommendations of a tumor board.  This metric was also used by Ribeiro, and 
provides tumor board physicians with a method to assess whether a given treatment 
regimen should be modified due to high toxicity.39  Measurement of operative 
mortality provides a similar measurement for surgical interventions, assessing the 
invasiveness of a treatment operation as it relates to mortality rate.  
Long-term survival 
 Unlike concordance data, long-term survival data have a great deal of 
variation, both in regards to raw data as well as statistical significance.  However, 
their documentation and analysis is crucial, given that the ultimate goal of cancer 
treatment (and treatment of any disease) is to avoid mortality and improve patient 
outcomes.    
 Many studies have pointed to long-term survival as a construct that is highly 
important in the evaluation of TBs.  Lamb points out the utility of survival data, 
stating that, “Traditional measures of outcome, such as survival data, give a robust 
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account of whether an intervention is effective or not.”33  Inherent in this issue is lead 
time bias, the idea that and increase in survival time after diagnosis may not 
necessarily be indicative of better disease management since the longer survival time 
may simply be accounted for by better screening procedures (Figure 1).33 However, 
Lamb also notes the importance of combining survival data with other short-term 
metrics.33  While Welch et al. have also pointed to the tracking and analysis of long-
term survival as illogical (due to the lead time bias) and call for use of other 
indicators to more effectively assess cancer interventions, survival of patients should 
still be tracked.48  The rationale behind the continued monitoring of patient survival is 
two-fold: a) patient survival is a primary goal of any disease treatment, b) Welch 
specifically mentions that it does have some connection to the quality of cancer care 
(albeit a tenuous one).  The second point demonstrates that patient survival could be 
useful if combined with other indicators. 
Figure 1: Lead Time Bias 
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 Moreover, many studies have used long-term survival as an indicator to show 
that multidisciplinary teams can improve patient outcomes.  A study by Junor et al. 
does show that use of multidisciplinary TBs enhanced 5-year survival of 
gynecological oncology patients at a statistically significant level.29  However, 
Birchall’s study of and English head-and-neck TB points to a slight decrease in 
survival, highlighting the great variability when using survival as an analytic tool.6  
Croke touches on this topic, stating that, “available [long-term survival] data are 
weakened by the heterogeneity and vagueness of the studies and their ill-defined 
endpoints and large number of confounding variables… As a result, firm conclusions 
cannot be drawn.”11  One method to increase the accuracy and validity derived from 
long-term survival measurements would be to increase sample size.  Even within 
cancer patient populations, death is a relatively rare and uncommon event.  By 
increasing the number of enrolled participants, the effects of participant variability 
would be mitigated, leading to increased validity. 
Diagnosis-Treatment Time (Time from Diagnosis to Treatment Initiation) 
 As designated in the title, this metric serves to measure how long a physician 
takes to implement the treatment recommended by the TB.  The construct that this 
indicator serves to measure is the assuredness of physicians in the chosen treatment; 
ideally, this assuredness would be improved through reinforcement of the literature-
based guidelines presented at TBs.  The idea of using diagnosis-treatment time as an 
effectiveness measurement tool was emphasized in Jazieh’s discussion of the role 
TBs play in cancer care.28  Jazieh states that development of this indicator, which 
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serves as a process evaluation tool to measure the expediency of carrying out TB 
consensus recommendations, could be used to measure the expediency of treatment 
and improve overall level of cancer care.28  Moreover, Gabel et al. showed that the 
use of a breast tumor board reduced diagnosis-treatment time from 42 days to 30 
days, corresponding with a greater percentage of curative therapies and greater patient 
satisfaction with the level of their care.20  Coory et al. also saw similar decreases with 
a lung TB.10 Despite this, it should be noted that not all studies have shown decreases 
in diagnosis-treatment times.  However, this indicator still provides a valuable 
measurement tool to measure the effect of TBs on physician assuredness.  As TBs are 
implemented, diagnosis-treatment times should continue to drop until reaching a 
threshold level.  Through measurement of diagnosis-treatment times, assuredness of 
physicians (in their management plans) and treatment expediency can be measured. 
“Before-and-After” Changes in Diagnosis and Treatment/Management  
 Before-and-after metrics are the most frequently used indicators to measure 
the effectiveness of TBs.  This involves comparing the pre-TB diagnosis, prognosis, 
and treatment administered by the covering physician with recommendations that 
were provided by consensus at the TB. The previous section outlined multiple studies 
using “before-and-after” indicators, with each tumor board experiencing varying 
levels of success in regards to changes in diagnosis and/or treatment plan. Thus, with 
an effective tumor board, we would initially expect to see a high rate of change for 
diagnosis and treatment.  
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 One of the main issues surrounding the use of before-and-after metrics to 
evaluate TB effectiveness (especially when they are used alone) is the confounding 
variables and biases that are inherent in the use of such indicators.  As mentioned by 
Lamb, studies using before-and-after measures alone do not assess whether the 
changes in diagnosis and treatment plan actually improve the quality of cancer care.  
Inherent in this issue is the fact that the before-and-after metric does not place any 
weight on the use of peer-reviewed treatment protocols.33  For example, changing 
from a frontline peer-reviewed treatment protocol to a less effective, non-reviewed 
protocol is still viewed as a “before-and-after” change, despite the fact that the 
efficacy may actually be lower.  Abdulrahman Jr. mentions this flaw, stating that the 
overall weakness of the before-and-after metrics does not control for confounding 
variables.1  This weakness does detract from the validity of before-and-after metrics; 
however, these indicators are still useful (when used in conjunction with other 
indicators) in measuring how ITBs change the clinical reasoning and treatment 
planning of physicians.  This can be seen by comparing before-and-after rates from 
immediately after ITB implementation to those long after implementation; over this 
time, before-and-after rates should steadily decrease, showing that physicians of the 
resource-constrained hospital have a better grasp of the most efficacious therapies 
(given in a resource-sensitive manner) and are utilizing these therapies before they are 
suggested in the ITB setting. 
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Qualitative Indicators 
 A number of recent studies have used qualitative indicators to measure 
constructs including physician education, improved care, and improved 
communication between members of care team.  Indicators such as rational for 
treatment discordance (discussed later), training/specialization of attendees, patient 
satisfaction, clinician’s perception of educational benefit, attendee’s perception of TB 
case load (too many or too few), case selection process, and attendee satisfaction, 
have been used to provide a qualitative aspect to TB assessment.9, 14, 20, 40  While these 
indicators should not be used alone, their use in conjunction with qualitative measures 
can provide the reasoning as to why certain results occur. 
Implications in Low-Resource Settings 
 The above section has outlined the current TB impact evaluation indicators 
and proposed a plan for moving forward with TB analysis.  The remainder of this 
discussion will serve as a discussion ground for the use of TBs in a low-resource 
setting, as well as how the analysis of such TBs would differ from other TBs. 
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TUMOR BOARDS ON AN INTERNATIONAL FRONT 
As stated before, the principle reason for the creation of tumor boards is to 
enhance the quality of cancer care and post-graduate education, both through case 
reviews and literature-based teaching.  If effective in these objectives, tumor boards 
would lower the mortality and morbidity of cancer as well as create ad-hoc guidelines 
for care (or improve physician knowledge of care guidelines if they already exist).  
To this end, the use of tumor boards could be extended to an international context, 
allowing for international case consultation as well as a learning experience enhanced 
by the variety of case presentations from clinicians working in multiple contexts; 
through international tumor boards, the scope of cancer care improvements moves 
from a domestic realm to a global one.24 This approach would be especially effective 
in low- and middle-income countries due to their relative lack of specialists, 
insufficiency of post-graduate training, and dearth of spending on non-communicable 
diseases.5, 14. 15  International tumor boards (ITBs) would allow participants to 
collaborate with and advise each other, resources they would not have access to 
otherwise.  Additionally, international TBs could provide physicians and care-
providers with exposure to regionally rare diseases and thus, enhance their knowledge 
about cancers common in other countries but rarely seen domestically.  For example, 
tumor boards could be used to educate European physicians and nurses on care of 
Kaposi’s sarcoma (seen predominantly in Central and Southern Africa), or to educate 
Japanese doctors on prostate cancer (seen infrequently in East Asia).42  Additionally, 
the use of tumor boards could contribute to the standardization and improvement of 
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resource-sensitive treatment plans for low- and middle-income countries.15  In this 
sense, TBs provide a great avenue for collaboration and improvement of care on an 
international scale; this point is even more relevant when partnering teams from 
developed nations to those of the undeveloped world (low- and middle-income 
countries).  
Benefits of ITBs 
 The major benefits of ITBs are listed in Table 6.  As outlined by Eniu, 
international tumor boards help to outline alternative therapies to a given cancer 
based on the resources available to low- and middle-income countries (LMCs).15  
Frontline therapies are often not available in these settings as a result of high drug 
costs, lack of trained specialists, and inaccessibility of advanced facilities and/or 
therapeutic machines (Ex. Radiation therapy, Immunohistochemistry).15  Through the 
use of international tumor boards to discuss resource-sensitive alternative cancer 
therapies in addition to mentioning frontline therapies, these conferences allow for a 
sustainable and cost-effective avenue of improving care in LMCs.  These alternative 
therapies can then be compiled into a set of treatment protocols based on the 
resources of the hospital.  This can serve as a stop-gap solution for the short or long 
term until the government of the LMC is able to allocate more money to cancer 
therapeutics, training clinicians, and other resource-related issues.15 This teaching 
capacity can be further extended via recording of the ITBs, both in terms of the 
audio/video feeds as well as the slides presented.24 
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 Anderson mentions that through the training experience gained via ITBs, 
LMCs can avoid the “brain drain” that occurs through trainees leaving the country in 
order to get advanced training.  To this end, he mentions a program between Ghana 
and Norway aimed at improving surgical cancer treatment while limiting the travel 
costs for Ghanaian surgeons.  Through such programs involving further training of 
trainees and junior physicians, younger physicians may find domestic opportunities 
more attractive than before, thus reducing the effect of the “brain drain”.5 
 One of the potential pitfalls in developing international tumor boards with 
hospitals of LMCs is that a large number of these hospitals will lack the treatment 
technology and/or communication technology to make these tumor boards effective.  
In addition to having difficult obtaining use of radiation therapy or 
immunohistochemistry or appropriate specialists, hospitals may have issues gaining 
access to stable internet sources, cameras, or microphones needed for a TB.  In order 
to limit and possibly prevent these issues from arising, hospitals can develop 
partnerships with local hospitals in order to work together to gather the needed 
resources.  These partnerships, when formalized and structured, can lead to more 
productive inter-hospital collaboration, greater capacity on both sides, and further 
expand the scope of a TB with a hospital from a developed nation.  However, it 
should be noted that such inter-hospital partnerships could cause dependency and 
become unsustainable.  However, it should be noted that such partnerships should not 
serve to provide resource-limited hospitals with clinical tools (diagnostics, 
therapeutics, etc.), seeing as this practice is highly unsustainable in the long-term.  
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Partnerships should only serve to enhance the communication technology for 
resource-constrained hospitals, allowing them to engage in twinning partnerships that 
are more sustainable in the long-term. 
 
Barriers to international use 
Multiple issues must be dealt with before an international tumor board can get 
off the ground, despite initial interest in collaboration from both sides.   
The first issue is that a method of communication must be usable on both 
sides.  This involves both language barriers between teams as well as technological 
issues.  As for language barriers, use of an interpreter/translator is discouraged as it 
could cause further separation and alienation of teams, preventing group cohesion and 
participation.  Additionally, use of interpreters limits time efficiency, making tumor 
boards more time consuming than needed.  Thus, it is recommended that tumor 
boards be held in a language that is common to both teams where possible.  When no 
common language exists, an accredited interpreter with knowledge of medical 
Table 6: Benefits of ITBs Between Resource-limited and Resource-rich 
Clinicians: 
1. Production of resource-sensitive guidelines for resource-limited settings 
2. Development of protocols/algorithms for optimizing care efficacy 
3. Mitigating the effects of clinician shortages (“brain-drain”) 
4. Informal method to improve training of care-providers 
5. Gain communication technology to allow for partnerships 
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terminology should be used as an intermediary.  Regarding the technological barriers 
that may come up, protocols should be created beforehand to determine trouble-
shooting procedures.  When possible, one member of each team should attempt to set 
up a stable connection (audio, visual, etc.) 30-60 minutes before the start of the TB.  
This step will allow time to fix any glitches or issues that come up with minimal 
delay to the TB.  Ideal conditions would entail a stable internet connection allowing 
for a consistent audio and video connection (for sharing of slide presentations, 
radiology images, and pathology slides).  However, in order to troubleshoot faulty 
internet connections, alternative solutions with lower bandwidth requirements should 
be pursued.  This may entail using alternate web-conferencing clients, using an audio-
only connection, or even using telephone service to hold tumor boards.  Another 
viable alternative may include utilizing the technological equipment at a nearby 
facility to get a better connection for the ITB.  
The second large issue is the presentation of material, specifically involving 
technology and its use to broadcast images.  While domestic tumor boards can be 
conducted in person, the long-distance nature of international tumor boards 
necessitates the use of internet-based presentation techniques.  Thus, tumor board 
organizers need to find a presentation medium or application that best supports the 
needs of the tumor boards; specifically, the medium selected should allow clear oral 
communications without any time lag, as well as a method for either presenting slide 
presentations or uploading images (this becomes crucial with pathology and cytology 
slides as well as x-rays and other imaging).  Thus, the minimum requirements for a 
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presentation client are that both sides can view the slide presentation and engage in 
oral communication.  Communication platforms on which images for an ITB can be 
hosted are listed in Table 7.  While video transmission is ideal so that the members of 
each team can see each other (has potential to enhance collaboration), this is not 
necessary for the function of the tumor board.  In order to fulfill the requirement of 
basic image projection, both sides will need a video projector connected to a 
computer (if the ITB is to be viewed by large groups), and a microphone.  This  
solution is ideal when poor internet connectivity forces the ITB to occur via 
telephone.   If slide presentations are not viewable on one side, this issue can be 
circumvented by finding a web-based client that supports screen-sharing, allowing 
one side to look at the presentation via the screen of the other team (although this 
would require a stable internet connection).  If a video feed is also possible, each side 
will need a camera to establish this. 
Table 7: Presentation of Images During ITBs 
Method Description Advantages Disadvantages 
Video 
Transmission 
Teams switch 
between viewing 
each other and the 
slides 
Allows teams to see 
each other 
Requires large 
bandwidth, lags and 
crashes, requires 
multiple cameras 
Separate 
Transmission 
Teams have no 
visual connection, 
and advance through 
a slide presentation 
separately 
Works in low 
bandwidth, no 
hardware required 
(telephone), simple 
to transfer slide 
presentations 
Teams not able to 
form visual 
connections, teams 
may be on different 
slides without 
knowing 
Screen-
sharing 
One team projects 
their computer 
screen to the other 
while going through 
a presentation 
Free, easy to install 
software, ensures 
teams view same 
slide, less bandwidth 
than video 
No visual 
relationship 
between teams, can 
be high bandwidth, 
may lag 
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In addition to these problems (listed in Table 8), the problems of deploying a 
domestic TB in a developed nation also apply here, including variability between 
physicians/hospitals and delayed treatment start times.  Additional problems also 
exist in cancer care as it pertains to TBs, including issues with drug availability, 
palliation, improper technique, lack of treatment technology, and lack of follow-up.   
These issues will be discussed later sections. 
 
Current State of ITBs  
 Given the relative dearth of published journal articles and data-based analysis 
on TBs, there is an even smaller amount of knowledge on ITBs.  The need for ITBs is 
apparent in LMCs, especially given the aforementioned shortcomings of healthcare 
systems in these countries.  These shortcomings include a dearth of specialists, 
Table 8: Barriers to ITBs Between Resource-poor and Resource-rich 
Physicians: 
1. Language of communication must be consistent (ideally without 
interpreters) 
2. Technological resources on both sides should be able to support 
auditory communication 
3. Technological resources on both sides should allow for sharing of 
pathology, radiology, and other types of images 
4. A stable internet connection is not necessary, but is supremely 
helpful in facilitating collaboration 
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increasing cancer incidence rates, late-stage patient presentation, low levels of post-
graduate training, poorly executed diagnostic testing, poor drug availability, and little 
collaboration between hospitals3, 5, 14, 17  The presence of a partnership with a high 
resource hospital via a TB could help to partially or fully mitigate the effects of each 
of these issues.  However, many barriers exist to the development and effectiveness 
of TBs, including lack of accessibility, irregular meeting times, lack of pathologists 
(described by El Saghir as 25% of hospitals in Arab countries), poor attendance due 
to lack of attending physicians, lack of availability of pathology diagnostics, “brain-
drain” of physicians, late-stage presentation of patients, weak healthcare 
infrastructure, and poor availability and/or accessibility of drugs and other treatment 
modalities.5, 13, 14, 15, 52  El Saghir et al. note that, “Most low-resource countries lack 
the necessary health care system infrastructure to support multidisciplinary breast 
cancer care”, a statement that rings true across all types of neoplastic disease.14  These 
issues will be further discussed in a later section. 
 Some groups have attempted to set up international tumor boards, including 
the University of Minnesota-Poria Govt. Hospital partnership and the D-43 (Kenya- 
West Virginia University/ Ohio State University/ SUNY Upstate) partnership.  While 
these groups have not yet disclosed any data or information on patient outcomes, the 
existence of these partnerships is promising for the development of ITBs.  Other 
examples of international tumor boards do exist, such as the one mentioned by Adam 
et al.2  This international tumor board consists of a panel of experts creating a 
generalized protocol for treatment of this cancer.  As such, it does not apply to the 
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definition of ITB set out by this paper given that it does not focus on case-based 
discussions to improve care quality and post-graduate training at an LMC-based 
hospital.  Thus, international tumor boards of the type discussed here (ITBs) are 
scarce and the data produced from them is virtually non-existent in peer-reviewed 
journals at this stage. 
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BARRIERS TO CANCER TREATMENT IN DEVELOPING COUNTRIES AND 
THIER EFFECT ON ITB INDICATORS 
Intro 
 The following section will outline the barriers to cancer care that exist in 
developing countries as well as outline a methodology for either circumventing these 
issues or accounting for them in the impact evaluation of an ITB.  The development 
of more advanced and effective cancer therapeutics has come along in leaps and 
bounds over the last 40 years, with the development of care infrastructure, the use of 
multidisciplinary treatment teams, improved protocols, and support systems for 
families undergoing treatment.17, 39  Correct implementation and use of these 
advances is a reasonable and easily-achievable goal in resource-rich areas; however, 
as pointed out by Ribeiro and Ching-Hon, this proposition becomes infinitely more 
difficult in resource-poor areas.39  Many of the issues encountered in cancer care are 
based in the low access to technology and therapeutics, the underdevelopment of 
health care systems in developing countries, and the governmental priority (regarding 
funding) placed on infectious disease instead of non-communicable and chronic 
disease (including cancer). 5   
 These root causes then manifest themselves in many ways in tertiary-level 
care centers, including few oncology training programs, lack of availability of current 
diagnostic and therapeutic methods, few tertiary-level healthcare centers at which 
patients can receive treatment, late-stage presentation of neoplasias (and thus, poor 
prognosis), lack of evidence-based understanding of how treatment protocols should 
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differ in developing nations, few medical graduates to assist the few properly-trained 
oncologists, overburdened systems that subsequently are unable to appropriately 
address issues of psychosocial and emotional care, etc. (Table 9).5, 33  Moreover there 
are a number of factors that are wholly unrelated to the services provided by tertiary-
level cancer care institutions, yet still affect the effectiveness of care.  These include 
higher rates of smoking in the developing world, stigmatization surrounding cancer, 
lack of transport infrastructure to allow easy access to treatment centers, limited 
governmental funding for 
screening and prevention 
programs, poor financing 
schemes to support patients 
during their treatment, low 
quantity and quality of 
services provided by primary 
care physicians and 
community health workers, 
and the prevalence of HIV 
and HPV.17  In combination, 
these external issues alter the 
perceived efficacy of any 
cancer intervention in the 
developing world, and should 
Table 9: Problems Intrinsic to Tertiary-level 
Cancer Care Institutions in Developing 
Nations 
1. Few oncology training programs 
2. Unavailability of current diagnostic and 
therapeutic methods 
3. Few tertiary-level healthcare centers  
4. Lack of research on treatment protocols 
specific to developing nations 
5. Late-stage presentation of cases 
6. Few medical graduates to assist 
oncology-trained medical graduates 
7. Lack of emphasis on psychosocial care 
during treatment 
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be accounted for in impact evaluations.  
 All of the above factors effectively function as confounding variables in the 
analysis of ITB effectiveness, underestimating the effects of the tumor boards due to 
factors that are extrinsic and external to the tumor board itself.  Thus, the following 
section will discuss how the proposed indicators used in impact evaluations of ITBs 
are altered by the aforementioned factors. 
 
Physician Concordance 
 As mentioned before, concordance measures whether the physician delivers 
the treatment/management regimen that was suggested in the ITB.  Ideally, this 
number would be at or near 100%, showing that physician always implemented the 
consensus suggestions from the tumor board.  In studies based in developed nations, 
physician concordance from TBs is usually near 80%.  A study by Blazeby recorded 
85% for an Upper Gastrointestinal TB, El Saghir also noted 85% concordance across 
and Arabian Breast TB, while Schroeder saw a 78% concordance for an internet-
based gynecological TB, and Strong reported 86% for and Upper Gastrointestinal 
TB.7, 13, 40, 44   
 However, physician concordance could drop significantly (and remain low 
after implementation) with ITBs if resource-sensitive recommendations are not 
provided.  The relative lack of technology and appropriate therapeutics could create a 
low overall physician concordance.  This becomes an even bigger issue with hospitals 
based in low-income countries, simply because they often do not have the national 
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healthcare infrastructure to attain many of the current treatment modalities. This 
could entail not having a trained specialist to perform a treatment (ex. No oncologic 
surgeons in the entire nation), not having the appropriate materials to deliver a 
treatment (ex. No equipment to deliver radiation therapy), or both.   
These types of issues should be avoided based on the aforementioned use of 
resource-sensitive guidelines in ITBs.  By providing the resource-rich physicians with 
a list of treatments available to the resource-poor physicians as well as prompting 
them to adopt a collaborative attitude, physicians at ITBs could discuss both the 
frontline-therapy as well as a resource-sensitive treatment plan tailored to the 
materials of the resource-poor physicians.   
 When outside issues cause physicians into a state of non-concordance with the 
TB consensus, the rationale for such action should be recorded.  For example, if a 
drug supply chain issue caused a stock-out of the consensus therapy drug, the 
physician would be forced into discordance with the tumor board consensus; the lack 
of concordance, as well its causation by the drug stock-out, should be reported.  
Schroeder et al. took this additional step in their analysis, leading them to the 
conclusion that while they had only 78% concordance, much of the discordance was 
due to patient deterioration and subsequent modification of treatment, as shown by 
98% partial concordance of their physicians (showing that discordance was not due to 
lack of available resources).40  Moreover, Strong et al. qualified their observed 86% 
physician concordance by noting that 10% of the overall patient load (71% of the 
discordant cases) occurred due to patient decompensation.44  While the two 
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aforementioned studies stated decompensation as the main reason for physician 
discordance, it is possible that issues external to the clinician will have a similar or 
greater effect in causing physician discordance in the developing world. Thus, 
recording the rationale behind physician discord allows for a qualitative assessment 
of the barriers to care within that specific setting. 
Tumor Relapse Rate 
 The utility of measuring tumor relapse rate, as mentioned before, is to produce 
a greater amount of evidence regarding what treatments and therapies are the most 
effective.  When applied to the context of developing nations, this indicator becomes 
even more important given the variation in demographic characteristics and risk 
factors of developing country constituents.  Ribeiro and Ching-Hon touch on this 
concept in mentioning that more information on resource-poor contexts is needed due 
to variation in genetic and environmental factors that may play a role in the 
pathogenesis of cancer (and thus, affect treatment and prognosis).39   Farmer et al. 
make a more specific notation of such factors, including the higher rates of smoking 
in developing countries, the stigma associated with cancer, poor screening and 
prevention programs (causing late-stage presentation), higher incidence of HIV and 
HPV, etc.17  Additionally, Ribeiro et al. demonstrate that treatment abandonment 
rates are much higher in the developing world, resulting in higher relapse rates.39  As 
a result of the aforementioned factors, whose influence is not altered by ITBs, tumor 
relapse rates will likely remain higher in developing countries than in developed 
countries.  The implementation of ITBs, as well as any other cancer-targeting 
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intervention, is expected to lower the tumor relapse rate through suggesting treatment 
protocols whose efficacy has been demonstrated in peer-reviewed literature; however, 
it is unknown whether any given intervention would lower tumor relapse rates to the 
levels seen in the developing world, where frontline therapeutics are readily available 
and external conditions are ideal for minimizing the recurrence of tumors.   
 On the theme of monitoring relapse rates, Ribeiro states, “With the 
introduction of intensive, protocol-based chemotherapy…the relapse rate has 
decreased markedly, and the rate of treatment abandonment has decreased from 16% 
to less than 1%.  The use of more aggressive therapy has resulted in more deaths from 
infection and hemorrhage, but refinements in patient care have begun to ameliorate 
these complications.  The most recent analysis of event-free survival shows rates 
similar to those in some highly developed countries.”  Based on this commentary, we 
can expect relapse rates to initially start at a high level, but drop down to levels 
nearing those of the developed world once the ITB has been completely and 
effectively implemented.  However, it should be noted that this cannot occur without 
an improvement in clinical management of patients as they receive these therapies. 
Toxicity-based Death Rate/ Operative Mortality 
 As shown by the St. Jude Children’s- Recife Hospital twinning partnership 
(includes an ITB as well as other programs) described by Ribeiro and Ching-Hon, it 
should be expected that toxicity-related deaths would initially be high (in the initial 
phases of ITB implementation), but would decrease over time as a result of greater 
use of literature-proven treatment protocols.  Not only does this reflect better use of 
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therapeutics, but also better management of patients as they receive chemotherapy 
and radiation therapy.  Operative mortality, given that it serves to measure the harm 
done by surgical intervention, provides the same function as toxicity-based mortality 
for a different set of therapies.  However, the operative morality data of developing 
nations may never reach the same levels as developed nations, simply because of the 
late-stage presentation that exists in the developing world, unless stratified by stage at 
presentation (causes include stigma, poor screening and prevention programs, etc.) 
and the subsequent need for more radical surgical intervention.  Moreover, the lack of 
available treatment resources further compounds this issue and leaves the resource-
poor nations behind the developing world in operative mortality. 
Long-term Survival 
 From a survival point of view, we should expect that all datasets collected 
from resource-poor settings and/or low-income countries will have lower survival 
percentages that datasets collected from resource-rich, high-income countries.  This is 
a result of many different factors, including the higher quantity and quality of primary 
care and preventive care, better disease screening programs, a higher standard of 
living, better healthcare financing mechanisms, etc., in resource-rich settings.17  It 
should also be noted that as a result of the much less extensive healthcare 
infrastructure existent in most low-income countries, the ability to track former 
patients for survival is much lower and thus, leads to a greater number of patients lost 
to follow-up.5  For these reasons, survival percentages from the developing world 
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should never be compared to those from the developed world.  However, we would 
expect long-term survival to be improved as a result of ITB implementation. 
 Long-term survival of patients treated at resource-poor hospitals should not 
necessarily be drastically different form patients treated at resource-rich hospitals.  
While the developing world does have an overall lower life expectancy and higher 
annual mortality rate, this may not necessarily become a large factor in altering the 
long-term survival of cancer patients.  The reason for this, as mentioned by Welch et 
al., is the overall variability of patients used to calculate long-term survival.48  This 
could lead to systematic error and thus, reduces the viability of this indicator as a 
stand-alone measure of ITB effectiveness.  Still, given that it measures one of the 
constructs most heavily targeted by ITBs (life expectancy), it should still be measured 
and combined with other indicators to improve its validity. 
Diagnosis-Treatment Time (Time from Diagnosis to Treatment Initiation) 
 As mentioned before, diagnosis-treatment time is used to measure the 
assuredness of the physician in the consensus treatment from the ITB.  Diagnosis-
treatment times would likely decrease as a result of ITB implementation, given that it 
provides clinicians with reassurance and reinforcement for their treatment plan.  This 
is especially true for clinicians in LMCs, who may be less aware of current treatment 
guidelines.3, 27, 52  Given that ITBs entail the provision of resource-sensitive 
guidelines to resource-poor hospitals, diagnosis-treatment times of developing-world 
hospitals would be expected to decrease until reaching those of developing-world 
hospitals.  As discussed before, Jazieh has discussed the utility of this metric and 
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Gabel et al. showed that TBs can significantly reduce diagnosis-treatment time.20, 28  
Similar results regarding diagnosis-treatment time should be expected in evaluating 
ITB outcomes in developing countries.   
“Before-and-After” Changes in Treatment/Management and Diagnosis 
 As mentioned before, while these currently-used indicators are not necessarily 
the most valid measures of effectiveness, their utility can be enhanced when 
combined with the other aforementioned indicators.  Ideally, measuring the changes 
in diagnosis and treatment before and after an ITB would show the level to which 
improper and/or ineffective diagnoses and therapies have been corrected to those 
based in peer-reviewed literature.  Thus, using these indicators in tandem with 
indicators tracking patient outcomes would allow investigation of whether higher 
percentages of “before-and-after” changes do in fact correlate to a better quality of 
care.  Given that one of the main objectives of ITBs is to promote more effective and 
more common use of research-based resource-sensitive treatment protocols, it would 
be expected that the implementation of ITBs would causes the “before-and-after” 
metrics would reflect a high number of changes, especially in the initial phases of 
ITB implementation.  As time progresses, these before-and-after numbers would be 
expected to drop as a result of the resource-poor physicians developing a better 
understanding of the most effective therapies available at their disposal.   
 As mentioned before, these metrics are confounded by the fact that a change 
in either diagnosis or treatment protocol, as measured by the before-and-after 
indicators, does not necessarily reflect an improvement in care.  For this reason, it is 
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crucial that a) recommendations only be made based on peer-reviewed literature 
regarding cancer in low-resource settings (when possible), and b) data obtained on the 
outcomes of patients presented at ITBs be reviewed regularly to ensure that 
recommendations given by ITB physicians do in fact lead to better clinical outcomes.    
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INTERNATIONAL TUMOR BOARDS AS A SPRINGBOARD FOR FURTHER 
COLLABORATION 
 Rather than being a stand-alone intervention, ITBs should serve as the basis 
for the development of further projects allowing resource-rich and resource-poor 
hospitals to collaborate further.  Such collaboration, mentioned by Ribeiro et al. as 
“twinning partnerships”, can include trainee exchanges, teleconsultation services, and 
other interventions aimed at improving the quality of cancer care in resource-poor 
settings.  Twinning partnerships have been shown to decrease the rate of negative 
events surrounding cancer care, including treatment abandonment, toxicity, and 
relapses in tumor development.39  Such partnerships, which have been taking place at 
increasing rates over the last 10 years, allow hospitals to build momentum in 
improving the quality of care, jointly develop protocols with physicians of resource-
rich hospitals, gain the aid of other physicians in managing their patients via 
consultation, develop cancer registries to understand the burden of cancer, and 
provide a rallying point for charity groups.39  As such, the development of an ITB, 
especially after it has become fully and effectively implemented, can allow for 
additional interventions that work alongside the ITB to further increase patient 
outcomes. 
 Moreover, the development of ITBs can allow for greater research regarding 
the burden of disease in developing countries.   As mentioned by Farmer et al., this 
continues to be a large barrier to effective care in resource-poor settings given that 
there is little understanding of which therapies are successful and which are not in 
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resource-poor settings.17  Given that many developing countries differ from their 
developed counterparts in countless environmental factors as well as a number of 
genetic variables, more investigation needs to be done as to what the most effective 
treatments are in these settings.15  This is seen not only through a variation in therapy 
effectiveness, but a variation in disease burden itself.  The prevalence of certain 
cancers are much higher or lower in the developing world as compared to the 
developed world.  For example, while penile cancers represent only 0.5% of the 
cancer burden in the US and Europe, it represents nearly 10% of all cancers in 
developing nations.44  The drastic difference in frequency of penile cancer only 
further highlights the variability between the developed world and the developing 
world, and the subsequent need for more research regarding treatment efficacy in the 
developing world.   
ITBs aid in initiating research on cancer in the context of the developing 
world by a) providing a discussion ground on which doctors can further discuss the 
variability between resource-rich and resource-poor contexts, b) developing a running 
list of patients presented at ITBs alongside the diagnoses and therapies they received, 
and c) facilitating the development of twinning partnerships in which cancer registries 
including the (clinical therapy received) are created.  Through each of these 
pathways, more information will come to light regarding the variability of cancer 
treatment efficacy as it differs by context, further allowing for improved cancer care 
in resource-poor settings.  
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CONCLUSION 
 Tumor boards have gained momentum over the last 20 years, as shown by the 
increased implementation of TBs on a global scale and the 1995 Calman-Hine ruling.  
However, their use in a twinning partnership between hospitals of the developed and 
developing world is a relatively new notion, demonstrated by the relative lack of 
peer-reviewed literature on the topic.  While a handful of initiatives have sprouted up 
in recent years, data collection has not been initiated.  Given that domestic tumor 
boards have such poor evaluation metrics, new indicators of effectiveness need to be 
developed.  This paper serves to outline several metrics that should be used to 
measure TB effectiveness (international or otherwise), as well as to discuss how the 
barriers existent in low-resource settings would affect these indicators.  Throughout 
this discussion, one apparent theme is that no single indicator is sufficient to measure 
TB impact, and as such, multiple metrics need to be used in unison to gain a much 
deeper perspective into the true effect of TBs and ITBs.  Moreover, ITBs themselves 
should not exist in unison, but as the initial foundation for further collaboration 
between hospitals.  The development of “twinning” partnerships between hospitals 
can allow for further development of multiple aspects of care and improve the quality 
of services the patient receives. 
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